Protocol for a randomised trial testing a community fibrosis assessment service for patients with suspected non-alcoholic fatty liver disease: LOCal assessment and triage evaluation of non-alcoholic fatty liver disease (LOCATE-NAFLD).
Community-based management
Economic evaluation
Implementation evaluation
NAFLD
Non-alcoholic fatty liver disease
Protocol
Randomised controlled trials
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
21 Apr 2020
21 Apr 2020
Historique:
received:
07
04
2020
accepted:
15
04
2020
entrez:
23
4
2020
pubmed:
23
4
2020
medline:
8
10
2020
Statut:
epublish
Résumé
Non-alcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease in Australia and its recent increase mirrors the obesity and type 2 diabetes epidemics. Currently, many patients who present to primary care with abnormal liver function tests or steatosis on liver ultrasound are referred for assessment in secondary care. Due to the large number of patients with NAFLD, this results in long waits for clinical and fibrosis assessment, placing unnecessary burden on the public hospital system. We will conduct a 1:1 parallel randomised trial to compare two alternative models of care for NAFLD. Participants will be randomised to usual care or the LOCal Assessment and Triage Evaluation (LOCATE) model of care and followed for 1 year. We will recruit patients from the non-neighbouring Sunshine Coast and Metro South Hospital and Health Services (HHSs) in Queensland, Australia. Our primary outcome of interest is time to diagnosis of high-risk NAFLD, based on the number of participants in each arm of the study who receive a diagnosis of clinically significant fibrosis. Two hundred and 34 participants will give us a 95% power to detect a 50% reduction in the primary outcome of time to diagnosis of high-risk disease. We will also conduct an economic evaluation, evaluating the cost-effectiveness of the new model of care. We will also evaluate the implementation of the new model of care. It is anticipated that the results of this study will provide valuable new information regarding the management of NAFLD in the Australian setting. A relatively simple change to care could result in earlier identification of patients with significant liver disease and lower overall costs for the health system. Results will be directly disseminated to key staff for further distribution to consumers, policy- and decision-makers in the form of evidence briefs, plain language summaries and policy recommendations. The trial was registered on 30 January, 2020 and can be found via ANZCTR - number ACTRN12620000158965.
Sections du résumé
BACKGROUND
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) is the most common type of chronic liver disease in Australia and its recent increase mirrors the obesity and type 2 diabetes epidemics. Currently, many patients who present to primary care with abnormal liver function tests or steatosis on liver ultrasound are referred for assessment in secondary care. Due to the large number of patients with NAFLD, this results in long waits for clinical and fibrosis assessment, placing unnecessary burden on the public hospital system.
METHODS
METHODS
We will conduct a 1:1 parallel randomised trial to compare two alternative models of care for NAFLD. Participants will be randomised to usual care or the LOCal Assessment and Triage Evaluation (LOCATE) model of care and followed for 1 year. We will recruit patients from the non-neighbouring Sunshine Coast and Metro South Hospital and Health Services (HHSs) in Queensland, Australia. Our primary outcome of interest is time to diagnosis of high-risk NAFLD, based on the number of participants in each arm of the study who receive a diagnosis of clinically significant fibrosis. Two hundred and 34 participants will give us a 95% power to detect a 50% reduction in the primary outcome of time to diagnosis of high-risk disease. We will also conduct an economic evaluation, evaluating the cost-effectiveness of the new model of care. We will also evaluate the implementation of the new model of care.
DISCUSSION
CONCLUSIONS
It is anticipated that the results of this study will provide valuable new information regarding the management of NAFLD in the Australian setting. A relatively simple change to care could result in earlier identification of patients with significant liver disease and lower overall costs for the health system. Results will be directly disseminated to key staff for further distribution to consumers, policy- and decision-makers in the form of evidence briefs, plain language summaries and policy recommendations.
TRIAL REGISTRATION
BACKGROUND
The trial was registered on 30 January, 2020 and can be found via ANZCTR - number ACTRN12620000158965.
Identifiants
pubmed: 32316984
doi: 10.1186/s12913-020-05233-2
pii: 10.1186/s12913-020-05233-2
pmc: PMC7171744
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
335Subventions
Organisme : National Health and Medical Research Council
ID : GNT1175567
Références
Health Econ. 2004 Dec;13(12):1203-10
pubmed: 15386669
Int J Epidemiol. 2005 Feb;34(1):215-20
pubmed: 15333621
Intern Med J. 2018 Feb;48(2):144-151
pubmed: 29083080
Aust Fam Physician. 2013 Jul;42(7):444-7
pubmed: 23826593
J Diabetes Complications. 2018 Aug;32(8):799-804
pubmed: 29861312
Hepatol Commun. 2018 Aug 06;2(8):893-905
pubmed: 30094401
Addiction. 1993 Jun;88(6):791-804
pubmed: 8329970
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Semin Hematol. 2008 Jul;45(3):135-40
pubmed: 18582619
Epidemiology. 2015 Jan;26(1):122-9
pubmed: 25401453
BMJ. 2015 Feb 06;350:h681
pubmed: 25663096
Intern Med J. 2016 Apr;46(4):420-6
pubmed: 26762655
J Gastroenterol Hepatol. 2018 Jun;33 Suppl 1:1-11
pubmed: 29851153
Int J Mol Sci. 2016 May 20;17(5):
pubmed: 27213358
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
JAMA. 2007 Mar 21;297(11):1233-40
pubmed: 17374817
BMJ. 2014 Mar 07;348:g1687
pubmed: 24609605
Liver Int. 2017 Dec;37(12):1897-1906
pubmed: 28556413
Pharmacoeconomics. 2015 Dec;33(12):1245-53
pubmed: 26233836
Hepatology. 2016 Jan;63(1):138-47
pubmed: 26171685